Previous Article | Next Article 
Journal of Virology, December 1999, p. 9891-9898, Vol. 73, No. 12
0022-538X/99/$04.00+0
Ability of Foot-and-Mouth Disease Virus To Form
Plaques in Cell Culture Is Associated with Suppression of
Alpha/Beta Interferon
Jarasvech
Chinsangaram,
Maria
E.
Piccone,
and
Marvin J.
Grubman*
Plum Island Animal Disease Center, North
Atlantic Area, Agricultural Research Service, U.S. Department of
Agriculture, Greenport, New York 11944
Received 17 May 1999/Accepted 27 August 1999
 |
ABSTRACT |
A genetic variant of foot-and-mouth disease virus lacking the
leader proteinase coding region (A12-LLV2) is attenuated in both cattle
and swine and, in contrast to wild-type virus (A12-IC), does not spread
from the initial site of infection after aerosol exposure of bovines.
We have identified secondary cells from susceptible animals, i.e.,
bovine, ovine, and porcine animals, in which infection with A12-LLV2,
in contrast to A12-IC infection, does not produce plaques; this result
indicates that this virus cannot spread from the site of initial
infection to neighboring cells. Nevertheless, A12-LLV2 can infect these
cells, but cytopathic effects and virus yields are significantly
reduced compared to those seen with A12-IC infection. Reverse
transcription-PCR analysis demonstrates that both A12-LLV2 and A12-IC
induce the production of alpha/beta interferon (IFN-
/
) mRNA in
host cells. However, only supernatants from A12-LLV2-infected cells
have significant antiviral activity. The antiviral activity in
supernatants from A12-LLV2-infected embryonic bovine kidney cells is
IFN-
/
specific, as assayed with mouse embryonic fibroblast cells
with or without IFN-
/
receptors. The results obtained with cell
cultures demonstrate that the ability of A12-IC to form plaques is
associated with the suppression of IFN-
/
expression and suggest a
role for this host factor in the inability of A12-LLV2 to spread and
cause disease in susceptible animals.
 |
INTRODUCTION |
Foot-and-mouth disease (FMD) is a
highly contagious disease of cloven-hoofed animals that is spread by
aerosol. It is the most economically important disease of livestock
worldwide, and FMD-free countries enforce trade embargos of meat and
meat products on countries in which the disease is enzootic (1,
18). FMD is caused by a member of the Aphthovirus
genus of the family Picornaviridae. To control and eradicate
the disease, a chemically inactivated FMD vaccine is used along with
slaughter of infected and exposed animals and strict quarantine
measures (5). Although killed vaccines are effective, there
are recurrent problems and concerns, including escape of live virus
from manufacturing plants, improper virus inactivation, relatively
short-lived immunity, and development of a carrier state in some
vaccinated animals following contact with FMD virus (FMDV) (2, 13,
27). To overcome some of these difficulties, we have initiated a
program to develop live attenuated viruses based on our knowledge of
the virus and its mode of replication at the molecular level.
The FMDV genome is a positive-sense single-stranded RNA molecule of
about 8,300 nucleotides and codes for four primary translation products, leader (L), P1, P2, and P3, which are processed by the virus-encoded proteinases, L, 2A, and 3C, into the mature structural and nonstructural proteins (26). Translation initiates
internally, at the L coding region, in a cap-independent manner
directed by the internal ribosome entry site. The first translation
product, L, is a papain-like proteinase that cleaves itself from the
growing polypeptide chain (9, 10, 15, 23, 25, 31). Like the 2A proteinase of other picornaviruses, the L proteinase is essential for the rapid replication of FMDV because it also cleaves the host
initiation factor eIF-4G; this factor is required for the translation
of host mRNAs, most of which initiate translation by a cap-dependent
mechanism (9, 14, 19, 26). Since the translation of FMDV
mRNA is cap independent, the cleavage of eIF-4G results in the shutoff
of most host cell protein synthesis and the rapid synthesis of viral
proteins. In addition, as a result of the shutoff of host cell protein
synthesis, the ability of the host to mount an antiviral response may
be compromised.
We have constructed a genetic variant of FMDV lacking a complete L
proteinase coding region (22). The leaderless virus
(A12-LLV2) replicates slightly more slowly than the wild-type virus
(A12-IC) in baby hamster kidney cells (BHK-21 cells) and is slightly
attenuated in suckling mice (22). In contrast to A12-IC,
A12-LLV2 is nonpathogenic in bovine and porcine animals but replicates
and induces a neutralizing antibody response as well as partial
protection upon virulent virus challenge (6, 17). After
aerosol exposure of cattle to A12-LLV2, only a small number of isolated
cells in the respiratory bronchioles were found to be infected, and the
virus did not spread systemically to epidermal sites in the oral and
pedal regions (4). In contrast, A12-IC caused extensive
local infection and rapidly spread to secondary sites (4).
Based on these data, we hypothesized that L proteinase is a virulence
factor, the presence of which results in uncontested growth of virus
because of the inhibition of a host antiviral response and rapid viral
protein synthesis.
In this study, we have examined the host cell response to FMDV
infection in cell cultures by using bovine, ovine, and porcine cells
which are susceptible to A12-IC and A12-LLV2 infection but selectively
support the spread of only A12-IC. Virus replication was examined with
secondary embryonic bovine kidney (EBK), lamb kidney (LK), and porcine
kidney (PK) cells, and the induction of a host cell antiviral response
in A12-LLV2-infected cells was demonstrated. The molecular mechanisms
responsible for this phenomenon and their implications in disease
pathogenesis are discussed.
 |
MATERIALS AND METHODS |
Cells and viruses.
BHK-21 (clone 13) cells were used to
propagate virus stocks and to measure virus titers in plaque assays.
Secondary EBK, LK, and PK cells were provided by Carol House
(12). Immortalized mouse embryonic fibroblast (129) cells
from wild-type mice (+/+) and from mice lacking a subunit of the
alpha/beta interferon (IFN-
/
) receptor (
/
) were provided by
David E. Levy (16, 20). FMDV A12-IC was derived from the
full-length infectious clone pRMC35 (24), and
A12-LLV2 was derived from the infectious clone lacking the Lb coding
region, pRM-LLV2 (22). Vesicular stomatitis virus serotype
New Jersey (VSV-NJ) and bovine enterovirus serotype 1 (BEV-1) were
provided by Carol House and Jim House, respectively. In all assays, the
multiplicity of infection (MOI) used was based on titration in BHK-21 cells.
Single-step growth assay.
BHK-21, EBK, LK, and PK cells were
infected with A12-IC or A12-LLV2 at an MOI of 10 at 37°C. After
1 h of adsorption, cells were rinsed with 150 mM NaCl-20 mM
morpholineethanesulfonic acid (MES) (pH 6) to inactivate unadsorbed
input virus and incubated in minimal essential medium (MEM) at 37°C.
Supernatants were collected from the infected cell cultures at 1, 2, 4, 6, 7, and 24 h postinfection (hpi) and titrated on BHK-21 cells as
described previously (15).
PAGE.
EBK, LK, and PK cells were infected with A12-IC or
A12-LLV2 for 1 h and radiolabelled with
[35S]methionine at various times postinfection as
described previously (22). Cells were lysed, and cytoplasmic
extracts were analyzed by sodium dodecyl sulfate-15% polyacrylamide
gel electrophoresis (PAGE) as described previously (22).
Infection inhibition assay.
EBK, LK, PK, and BHK-21 cells
were infected with A12-LLV2 at MOIs of 0.01, 0.1, 1, and 10 for 1 h. Cells were rinsed as described above to inactivate unadsorbed virus
and rinsed with MEM to restore physiological pH. Infection was
continued for 4, 7, 24, and 48 h. Supernatants were obtained,
centrifuged to remove cellular debris, brought to pH 2 with
concentrated HCl, incubated for approximately 24 h at 4°C, and
restored to pH 7 with concentrated NaOH (28). Treated
supernatants were examined for the presence of FMDV by a plaque assay
on BHK-21 cells. The supernatants were serially diluted with MEM and
incubated for 24 h with homologous cells. All dilutions were
assayed in duplicate. The supernatants were removed, cells were washed
with MEM and infected with 50 to 100 PFU of A12-IC, VSV-NJ, or BEV-1,
and a plaque assay was performed.
To examine if the ability of FMDV to spread and form plaques was
suppressed by antiviral molecules in the supernatants, PK cells were
infected with approximately 100 PFU of A12-IC; at 1, 2, 3, and 4 hpi,
the supernatants were replaced either with a 1:10 dilution of treated
supernatants from A12-LLV2- or mock-infected PK cells or medium in a
gum tragacanth overlay for a plaque assay or with liquid medium without
an overlay for a total of 48 h. The growth of A12-IC in liquid
media was determined by a subsequent plaque titration assay on BHK-21 cells.
To confirm the specificity of IFN-
/
, dilutions of treated
supernatants from A12-IC- A12-LLV2-, or mock-infected EBK cells were
incubated for 24 h with +/+ or
/
129 cells. Cells were then
infected with 50 to 200 PFU of VSV-NJ, and a plaque assay was performed.
Infective-center assay.
EBK and LK cells were infected with
A12-LLV2 or A12-IC at an MOI of 10. At 1 hpi, cells were trypsinized,
washed twice with MEM, and treated with 150 mM NaCl-20 mM MES (pH 6)
to inactivate virus that was not internalized. Cells were then rinsed
with MEM and counted. These cells were diluted 10-fold and inoculated, in duplicate, onto a BHK-21 cell monolayer for plaque titration (29). The number of plaques relative to the number of EBK or LK cells that were originally seeded onto the BHK-21 cell monolayer was
reported as an infection index. The infection index of both viruses on
BHK-21 cells was 1.
RT-PCR.
EBK, LK, or PK cells were infected with A12-IC or
A12-LLV2 at an MOI of 10. Cells were harvested at 6 hpi, and
polyadenylated mRNA was extracted by use of a Micro Poly(A)Pure Kit
(Ambion, Austin, Tex.). Samples were treated with DNase, and reverse
transcription (RT) reactions were performed with random hexamers.
Bovine primers for IFN-
and IFN-
, designed from available
sequences in the GenBank database, were used in assays with EBK and LK
cells, and the equivalent porcine and mouse primers (16)
were used in assays with PK and BHK-21 cells, respectively. All
qualitative PCR assays were performed for 40 cycles by use of separate
tubes with aliquots from RT reactions and IFN-
, IFN-
, or
-actin primers (7). PCR products were sequenced to
confirm their specificity. All samples were tested by RT-PCR without
reverse transcriptase to demonstrate that the positive signals observed
were from mRNA targets and not from contaminating DNA.
 |
RESULTS |
Replication of A12-IC and A12-LLV2 in secondary cells.
Secondary EBK, LK, and PK cells as well as BHK-21 cells are highly
susceptible to A12-IC (Fig. 1) (12, 22). In contrast, no
plaques were observed after infection of EBK, LK, and PK cells with
A12-LLV2 (Fig. 1 and
2). However, in BHK-21 cells, A12-LLV2 grew to high titers and formed plaques, although A12-LLV2 infection resulted in slightly lower yields than A12-IC infection (Fig. 1 and
3) (22). To determine if
A12-LLV2 could replicate in EBK, LK, and PK cells, single-step growth
experiments were performed, and samples were titrated on BHK-21 cells.
A12-LLV2 grew much more slowly than A12-IC, and the yield was
significantly lower in these cells than after A12-IC infection (Fig.
3).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Titers of A12-IC and A12-LLV2 on different cells.
BHK-21, LK, EBK, and PK cells were infected with A12-IC
( ) and A12-LLV2 ( ). Cells were overlaid
and incubated for 48 h before staining. A12-LLV2 did not form
plaques on LK, EBK, and PK cells and is reported as having no titer
detectable on these cell types in a plaque assay.
|
|

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 2.
Plaque titration on EBK cells. EBK cells were infected
with A12-LLV2 (A) at MOIs of 10, 1, and 0.1 (from left to right) or
A12-IC (B) at MOIs of 0.01, 0.001, and 0.0001 (from left to right) at
37°C for 1 h and then overlaid. Cells were stained at 48 h
postinoculation.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Single-step growth curve. BHK-21, EBK, LK, and PK cells
were infected with A12-LLV2 ( ) or A12-IC ( ) at an MOI of 10 at
37°C. After 1 h, cells were rinsed with 150 mM NaCl-20 mM MES
(pH 6.0) and incubated in MEM at 37°C. Supernatants were collected
from the infected cells at 1, 2, 4, 6, 7, and 24 h postinoculation
and titrated on BHK-21 cells.
|
|
Cytopathic effects (CPE) were observed in A12-IC-infected EBK cells
beginning at 3 hpi, and the cell sheet was completely destroyed between
8 and 24 hpi (Fig. 4). In contrast, CPE
were first observed in A12-LLV2-infected EBK cells at 4 hpi, but by 24 hpi, only approximately 15 to 20% of the cell sheet was destroyed. The
remainder of the sheet was intact, although it appeared altered compared to that of mock-infected cells; i.e., the cells had a darker
appearance and the monolayer had lost its characteristic swirling
pattern (Fig. 4). Similar results were obtained with LK and PK cells.
A12-IC infection of BHK-21 cells was similar to that of other cell
types, while A12-LLV2 infection resulted in delayed CPE (apparent at 6 hpi). However, in contrast to the results for A12-LLV2-infected
secondary cells, by 24 hpi CPE were observed in 90 to 95% of the cell
sheet (data not shown).

View larger version (135K):
[in this window]
[in a new window]
|
FIG. 4.
CPE in A12-IC- and A12-LLV2-infected EBK cells. EBK
cells were infected with A12-IC or A12-LLV2 or mock infected at an MOI
of 10 at 37°C for 1 h and then incubated in MEM. Cells were
formalin fixed at 3, 4, 6, 8, and 24 h postinoculation (PI).
|
|
To demonstrate that the difference in CPE between A12-IC- and
A12-LLV2-infected EBK and LK cells was not the result of different binding efficiencies of these viruses, an infective-center assay was
performed. EBK and LK cells were infected with A12-IC and A12-LLV2 at
an MOI of 10 (based on titration in BHK-21 cells) for 1 h and acid
treated to remove unadsorbed virus, 10-fold dilutions of cells were
inoculated onto a BHK-21 cell monolayer for 1 h, and a plaque
assay was performed to quantitate the number of cells harboring virus.
We found that both viruses actually infected only 30% of EBK cells and
that A12-IC and A12-LLV2 infected 50 and 70% of LK cells,
respectively, demonstrating that these viruses have similar binding efficiencies.
Protein synthesis in infected cells.
We previously showed that
in A12-LLV2-infected BHK-21 cells, host cell protein synthesis shutoff
and viral protein synthesis were delayed compared to those in
A12-IC-infected cells (22). In A12-IC-infected EBK cells,
viral proteins were first observed between 2 and 3 hpi, reached a
maximum between 3 and 4 hpi, and declined by 4 to 5 hpi, concomitant
with the destruction of the cell sheet (Fig.
5). The shutoff of host cell protein
synthesis in A12-IC-infected cells correlated with the increase in
viral protein synthesis (Fig. 5, compare lane 1 with lanes 2 through 6). In contrast, only a very low level of viral protein synthesis was
observed in A12-LLV2-infected cells, and there was a delay in the
shutoff of host cell protein synthesis (Fig. 5, compare lanes 3 and 8)
prior to the global inhibition of translation, as we previously showed
for BHK-21 cells (22) and as has been documented for other
picornavirus-infected cells (3, 8, 21). Identical results
were obtained with infected LK and PK cells (data not shown).

View larger version (112K):
[in this window]
[in a new window]
|
FIG. 5.
Protein synthesis in A12-IC- and A12-LLV2-infected EBK
cells. EBK cells were infected with A12-IC or A12-LLV2 for 1 h and
radiolabelled with [35S]methionine at various times
postinoculation for 1 h. Cells were lysed, and equal volumes of
cytoplasmic extracts were analyzed by sodium dodecyl sulfate-15%
PAGE. Lane 1 is a cytoplasmic extract of mock-infected EBK cells (M).
Lanes 2 to 6 show proteins from A12-IC-infected EBK cells radiolabelled
at 2, 3, 4, 5, and 6 h postinoculation, respectively. Lanes 7 to
11 show proteins from A12-LLV2-infected EBK cells radiolabelled at 2, 3, 4, 5, and 6 h postinoculation, respectively. Host cell proteins
revealed in mock-infected and infected cells are indicated by
asterisks.
|
|
Host cell antiviral response.
To investigate the factors
involved in the inability of A12-LLV2 to spread in secondary cells, we
examined supernatants from infected EBK, LK, PK, and BHK-21 cells for
antiviral activity. Cells were infected with A12-LLV2 at various MOIs
and for various lengths of time. Supernatants were obtained, treated at
pH 2 for 24 h, and neutralized. No virus was detected in treated
supernatants by a plaque assay on BHK-21 cells. Fresh cells were
incubated for 24 h with treated supernatants from homologous cells
and infected with a known amount of A12-IC, and a plaque assay was
performed. The supernatants harvested from A12-LLV2-infected EBK, LK,
and PK cells inhibited A12-IC plaque formation, while the supernatants harvested from A12-LLV2-infected BHK-21 cells and all mock-infected cells had no antiviral activity (Table
1). The ability of A12-LLV2 to spread
from the initial site of infection to form plaques in BHK-21 cells
correlates with the absence of a host cell antiviral response in these
cells, as measured in our assay. Supernatants from A12-IC-infected
cells contained either no antiviral activity (PK cells) or considerably
less antiviral activity than those from A12-LLV2-infected cells (EBK
and LK cells) (Table 1). The maximum inhibitory effect was obtained
with supernatants from cells infected with A12-LLV2 at an MOI of 1 or
10 after 24 h of infection. Supernatants from cells infected at a
lower MOI, i.e., 0.01 or 0.1, or from cells infected for shorter or
longer periods of time, i.e., 4, 7, or 48 h, yielded reduced or no
antiviral activity. Supernatants from A12-LLV2-infected EBK cells also
inhibited plaque formation of VSV-NJ and BEV-1, and supernatants from
A12-LLV2-infected PK cells inhibited plaque formation of VSV-NJ (Table
1).
The ability of A12-IC to spread and form plaques in PK cells was
clearly suppressed by supernatants from A12-LLV2-infected PK cells.
A12-IC formed small or poorly defined plaques when incubated with these
supernatants, and the suppression was apparent even after the A12-IC
infection had progressed for 4 h prior to treatment. Supernatants
from mock-infected PK cells or medium alone did not have any effect.
The suppression of A12-IC infection in the presence of
A12-LLV2-infected PK cell supernatants also resulted in a significant reduction (approximately 600- to 2,000-fold) in virus yield (Fig. 6).

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 6.
Reduction of virus yield in the presence of antiviral
activity. PK cells were infected with approximately 100 PFU of A12-IC;
at 1, 2, 3, and 4 hpi, the supernatants were replaced with a 1:10
dilution of treated supernatants from A12-LLV2-infected PK cells
( ), mock-infected PK cells ( ), or medium
alone ( ) for a total of 48 h. The growth of A12-IC
was determined in a subsequent plaque titration assay on BHK-21
cells.
|
|
The antiviral response is IFN-
/
specific.
The production
of IFN-
/
is one of the initial host responses to viral infections
(32). To determine if IFN-
/
mRNA was induced in
infected EBK cells, RT-PCR was performed. As shown in Fig.
7, IFN-
and IFN-
mRNAs were induced
in both A12-IC- and A12-LLV2-infected EBK cells but not in
mock-infected cells. Similar results were obtained with infected LK,
PK, and BHK-21 cells (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
RT-PCR for IFN- and IFN- mRNAs. EBK cells were
infected with A12-IC or A12-LLV2 or mock infected for 6 h and used
in RT-PCR as described in Materials and Methods. Aliquots from RT
reactions were used in three separate PCR assays with IFN- , IFN- ,
and -actin primers. RT-PCR products from EBK cells infected with
A12-IC (IC) or A12-LLV2 (LLV) or mock infected (M) in the presence or
absence of reverse transcriptase (RT) are shown. IFN- (A), IFN-
(B), and -actin (B) RT-PCR products are 379, 452, and 890 bp,
respectively. Lanes MW are 1-kb ladder DNA molecular weight markers.
|
|
In contrast to A12-IC infection, we have demonstrated that the
continuation of host cell protein synthesis in A12-LLV2-infected EBK,
LK, and PK cells allows the host to express an antiviral response that
could be involved in the inhibition of the spread of virus to
neighboring uninfected cells. The stability of antiviral activity
present in supernatants after pH 2 treatment and its ability to inhibit
the spread of other viruses, including VSV-NJ and bovine enterovirus,
are characteristic of IFN-
/
. In addition, we found that
antibodies against porcine or human IFN-
partially inhibited the
antiviral activity present in supernatants of A12-LLV2-infected PK or
EBK cells, respectively (data not shown). To further demonstrate that
this antiviral activity is IFN-
/
specific, we used fibroblast cell lines derived from wild-type mice (+/+ 129) or IFN-
/
receptor-negative mice (
/
129) (16, 20). In this system,
+/+ 129 but not
/
129 cells respond via a signal transduction
pathway to IFN-
/
and become resistant to viral infection.
However, antiviral activity that is not IFN-
/
specific affects
both cell lines equally.
In preliminary experiments, we found that 129 cells were refractory to
FMDV type A12. To overcome this problem, we assayed treated
supernatants from infected EBK cells on 129 cells, since IFN-
/
activity has been demonstrated in heterologous systems (11).
We selected VSV-NJ as the test virus for antiviral activity, since we
found that VSV-NJ can replicate in 129 cells. Supernatants from
A12-IC-, A12-LLV2-, or mock-infected EBK cells were incubated with +/+
129 or
/
129 cells for 24 h, and these cells were examined for
resistance to infection by VSV-NJ in a plaque assay. In this assay,
supernatants from A12-LLV2-infected EBK cells yielded 32 U of
heterologous antiviral activity on +/+ 129 cells, while supernatants from A12-IC- and mock-infected EBK cells had no activity (<2 U; Table
2). Neither A12-IC-, A12-LLV2-, nor
mock-infected EBK cell supernatants had antiviral activity on
/
129 cells (<2 U; Table 2).
 |
DISCUSSION |
Wild-type FMDV (A12-IC) spreads rapidly within the infected animal
from its site of entry to cause debilitating vesicular lesions by 1 to
3 days (4, 6, 17). In contrast, a genetic variant of FMDV
lacking the complete coding region for the nonstructural L protein
(A12-LLV2) is attenuated in cattle and swine (6, 17). After
aerosol exposure of cattle to A12-LLV2, only occasional single-cell
staining of viral RNA was found around respiratory bronchioles, in
contrast to an extensive local infection by A12-IC (4). In
addition, A12-LLV2 did not spread systemically to highly susceptible
sites in the oral and pedal regions (4). Since efficacy
studies of A12-LLV2 in cattle and swine demonstrated only low
neutralizing antibody titers by 3 days postinoculation (unpublished
observations), the inability of this virus to spread after aerosol
exposure must be the result of mechanisms other than the presence of
antibody. Other workers have shown that FMDV strains modified by
passage in alternate hosts or repeated passage in cell cultures are
avirulent in cattle and, in contrast to animal-virulent virus, can
induce the production of IFN (30). It was suggested that the
lack of virulence in cattle was correlated with increased IFN
production (28). However, no studies of these viruses at the
genome level have been performed to identify the mutation(s) responsible for attenuation and increased IFN induction.
To understand the molecular basis of the events involved in the
inhibition of the spread of A12-LLV2, we screened in vitro cell culture
systems for the inability of A12-LLV2 to form plaques on cells which
are highly susceptible to A12-IC and identified secondary bovine,
ovine, and porcine cells that displayed this selectivity. The detection
of IFN-
/
mRNA in EBK, LK, PK, and BHK-21 cells upon infection
with either virus in a qualitative RT-PCR assay demonstrates that these
viruses are IFN inducers.
Although IFN-
/
mRNA was induced in infected BHK-21 cells, the
absence of antiviral activity in the supernatants, as we (Table 1) and
others (30) have reported, suggests a defect in some aspect
of the IFN signal transduction pathway and/or IFN-regulated cellular
proteins in these cells. We have shown that A12-LLV2 can replicate to
high titers and form plaques in BHK-21 cells. The high yield and the
ability of A12-LLV2 to spread from its initial site of infection to
form plaques in BHK-21 cells correlate well with the absence of
antiviral activity in these cells.
We demonstrated an antiviral response in secondary EBK, LK, and PK
cells upon A12-LLV2 infection; this response was significantly greater
than that induced by A12-IC, reflecting the rapid inhibition of host
cell protein synthesis in A12-IC-infected cells. No antiviral activity
was found in A12-IC-infected PK cell supernatants; however, when
exposed to antiviral molecules present in A12-LLV2-infected PK cell
supernatants, the A12-IC phenotype could be altered toward that of
A12-LLV2, i.e., reduced spread and yield. The antiviral activity
present in the supernatants of A12-LLV2-infected EBK cells is
IFN-
/
specific, since it is biologically active after pH 2 treatment, inhibits the replication of wild-type FMDV as well as other
viruses and, most importantly, is demonstrated only on cells with
IFN-
/
receptors, as assayed in the 129 cell system.
Deletion of the coding region for the L proteinase of FMDV has resulted
in the inability of A12-LLV2 to spread from the initial site of
infection in the secondary cells examined. At least two factors have
contributed to this phenomenon, including the slow replication of
A12-LLV2 and the induced expression of IFN-
/
in A12-LLV2-infected
cells. The inability of this virus to inhibit host cell protein
synthesis at early times after infection results in competition between
viral and host mRNAs for the protein synthesis machinery and, as a
consequence, a slower rate of virus replication compared to that seen
with A12-IC infection. However, competition alone is not sufficient to
prevent the spread of A12-LLV2 from its initial site of infection to
form plaques in a cell line (BHK-21) that lacks a detectable antiviral
response. We have also demonstrated that A12-IC can become attenuated
in PK cells in the presence of antiviral activity, further supporting
the observation that differences in the rate of replication between
A12-IC and A12-LLV2 alone cannot account for the differences in their
infectivity. Thus, the expression of IFN-
/
, resulting in the
development of an antiviral state in neighboring cells, is necessary
for a higher degree of attenuation of A12-LLV2. A low level of
antiviral activity is also detected in A12-IC-infected EBK and LK cells (Table 1). However, the small quantity of antiviral activity produced
in wild-type virus-infected cells in the presence of levels of virus
significantly higher than those produced in A12-LLV2-infected cells
(Fig. 3) is apparently insufficient to provide resistance to infection.
The rapid onset of FMDV infection is generally attributed to the
ability of the virus to shut off host cell cap-dependent protein
synthesis, thereby diverting the host cell machinery to virus
production. In this study, we have demonstrated that, as a consequence
of host cell protein synthesis shutoff, the virus also prevents the
host from expressing IFN-
/
. The combination of these two events
results in rapid virus growth and spread. Deletion of the L proteinase
eliminates the ability of the virus to inhibit the host cell response
and consequently attenuates the virus. However, the possibility that
host factors besides IFN-
/
may also be involved in virus
attenuation cannot be ruled out. Studies with both our in vitro cell
culture system and susceptible animals should lead to a better
understanding of the host cell response to FMDV infection and may allow
the development of improved disease control strategies.
 |
ACKNOWLEDGMENTS |
We thank Marla Zellner for technical assistance; Carol House and
Jim House, PIADC, Foreign Animal Disease Diagnostic Laboratory, for
EBK, LK, and PK cells as well as VSV-NJ and BEV-1; David E. Levy, New
York University School of Medicine, for +/+ and
/
129 cells; and
Sabine Riffault, Unité de Virologie et Immunologie Moléculaires, INRA, 78352 Jouy-en-Josas Cedex, France, for rabbit polyclonal antibody against recombinant porcine IFN-
1.
We also acknowledge the Binational Agriculture Research and Development
Fund for financial support (grant US-2417-94).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Plum Island
Animal Disease Center, USDA, ARS, NAA, P.O. Box 848, Greenport, NY
11944. Phone: (516) 323-3329. Fax: (516) 323-2507. E-mail:
mgrubman{at}asrr.arsusda.gov.
Present address: Instituto de Biotecnología, CICV-INTA,
C.C. 77 (1708) Morón, Buenos Aires, Argentina.
 |
REFERENCES |
| 1.
|
Bachrach, H. L.
1978.
Foot-and-mouth disease: world-wide impact and control measures, p. 299-310.
In
E. Kurstak, and K. Maramorosch (ed.), Viruses and environment. Academic Press, Inc., New York, N.Y
|
| 2.
|
Beck, E., and K. Strohmaier.
1987.
Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination.
J. Virol.
61:1621-1629[Abstract/Free Full Text].
|
| 3.
|
Black, T. L.,
B. Safer,
A. Hovanessian, and M. G. Katze.
1989.
The cellular 68,000-Mr protein kinase is highly autophosphorylated and activated yet significantly degraded during poliovirus infection: implications for translational regulation.
J. Virol.
63:2244-2251[Abstract/Free Full Text].
|
| 4.
|
Brown, C. C.,
M. E. Piccone,
P. W. Mason,
T. S.-C. McKenna, and M. J. Grubman.
1996.
Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in bovines.
J. Virol.
70:5638-5641[Abstract/Free Full Text].
|
| 5.
|
Brown, F.
1992.
New approaches to vaccination against foot-and-mouth disease.
Vaccine
10:1022-1026[Medline].
|
| 6.
|
Chinsangaram, J.,
P. W. Mason, and M. J. Grubman.
1998.
Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus.
Vaccine
16:1516-1522[Medline].
|
| 7.
|
Degen, J. L.,
M. G. Neubauer,
S. J. Freizner-Degen,
C. E. Seyfried, and D. R. Morris.
1983.
Regulation of protein synthesis in mitogen-activated bovine lymphocytes. Analysis of actin-specific and total mRNA accumulation and utilization.
J. Biol. Chem.
258:12153-12162[Abstract/Free Full Text].
|
| 8.
|
DeStefano, J.,
E. Olmstead,
R. Panniers, and J. Lucas-Lenard.
1990.
The subunit of eucaryotic initiation factor 2 is phosphorylated in mengovirus-infected mouse L cells.
J. Virol.
64:4445-4453[Abstract/Free Full Text].
|
| 9.
|
Devaney, M. A.,
V. N. Vakharia,
R. E. Lloyd,
E. Ehrenfeld, and M. J. Grubman.
1988.
Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex.
J. Virol.
62:4407-4409[Abstract/Free Full Text].
|
| 10.
|
Gorbalenya, A. E.,
E. V. Koonin, and M. M.-C. Lai.
1991.
Putative papain-related thiol proteases of positive-strand RNA viruses: identification of rubi- and aphthovirus proteases and delineation of a novel conserved domain associated with proteases of rubi-, -, and coronaviruses.
FEBS Lett.
288:201-205[Medline].
|
| 11.
|
Gresser, I.,
M.-T. Bandu,
D. Brouty-Boye, and M. Tovey.
1974.
Pronounced antiviral activity of human interferon on bovine and porcine cells.
Nature
251:543-545[Medline].
|
| 12.
|
House, C., and J. A. House.
1989.
Evaluation of techniques to demonstrate foot-and-mouth disease virus in bovine tongue epithelium: comparison of the sensitivity of cattle, mice, primary cell cultures, cryopreserved cell cultures and established cell lines.
Vet. Microbiol.
20:99-109[Medline].
|
| 13.
|
King, A. M. Q.,
B. O. Underwood,
D. McCahon,
J. W. I. Newman, and F. Brown.
1981.
Biochemical identification of viruses causing the 1981 outbreaks of foot-and-mouth disease in the UK.
Nature
293:479-480[Medline].
|
| 14.
|
Kirchweger, R.,
E. Ziegler,
B. J. Lamphear,
D. Waters,
H.-D. Liebig,
W. Sommergruber,
F. Sobrino,
C. Hohenadl,
D. Blass,
R. E. Rhoads, and T. Skern.
1994.
Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4 .
J. Virol.
68:5677-5684[Abstract/Free Full Text].
|
| 15.
|
Kleina, L. G., and M. J. Grubman.
1992.
Antiviral effects of a thiol protease inhibitor on foot-and-mouth disease virus.
J. Virol.
66:7168-7175[Abstract/Free Full Text].
|
| 16.
|
Marie, I.,
J. E. Durbin, and D. E. Levy.
1998.
Differential viral induction of distinct interferon- genes by positive feedback through interferon regulatory factor-7.
EMBO J.
17:6660-6669[Medline].
|
| 17.
|
Mason, P. W.,
M. E. Piccone,
T. S.-C. McKenna,
J. Chinsangaram, and M. J. Grubman.
1997.
Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate.
Virology
227:96-102[Medline].
|
| 18.
|
McCauley, E. H.,
N. A. Aulaqi,
J. C. New,
W. B. Sundquist, and W. M. Miller.
1979.
A study of the potential economic impact of foot-and-mouth disease in the United States. U.S.
Government Printing Office, Washington, D.C.
|
| 19.
|
Medina, M.,
E. Domingo,
J. K. Brangwyn, and G. J. Belsham.
1993.
The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities.
Virology
194:355-359[Medline].
|
| 20.
|
Muller, U.,
U. Steinhoff,
L. F. L. Resi,
S. Hemmi,
J. Pavlovic,
R. M. Zinkernagel, and M. Aguet.
1994.
Functional role of type I and type II interferons in antiviral defense.
Science
264:1918-1921[Abstract/Free Full Text].
|
| 21.
|
O'Neill, R. E., and V. R. Racaniello.
1989.
Inhibition of translation in cells infected with a poliovirus 2Apro mutant correlates with phosphorylation of the alpha subunit of eucaryotic initiation factor 2.
J. Virol.
63:5069-5075[Abstract/Free Full Text].
|
| 22.
|
Piccone, M. E.,
E. Rieder,
P. W. Mason, and M. J. Grubman.
1995.
The foot-and-mouth disease virus leader proteinase gene is not required for viral replication.
J. Virol.
69:5376-5382[Abstract].
|
| 23.
|
Piccone, M. E.,
M. Zellner,
T. F. Kumosinski,
P. W. Mason, and M. J. Grubman.
1995.
Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus.
J. Virol.
69:4950-4956[Abstract].
|
| 24.
|
Rieder, E.,
T. Bunch,
F. Brown, and P. W. Mason.
1993.
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice.
J. Virol.
67:5139-5145[Abstract/Free Full Text].
|
| 25.
|
Roberts, P. J., and G. J. Belsham.
1995.
Identification of the critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease.
Virology
213:140-146[Medline].
|
| 26.
|
Rueckert, R. R.
1996.
Picornaviridae: the viruses and their replication, p. 609-654.
In
B. N. Fields, D. M. Knipe, and P. H. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa
|
| 27.
|
Salt, J. S.
1993.
The carrier state in foot-and-mouth disease virus an immunological review.
Br. Vet. J.
149:207-223[Medline].
|
| 28.
|
Sellers, R. F.
1963.
Multiplication, interferon production and sensitivity of virulent and attenuated strains of the virus of foot-and-mouth disease.
Nature (London)
198:1228-1229[Medline].
|
| 29.
|
Sellers, R. F.
1964.
Virulence and interferon production of strains of foot-and-mouth disease virus.
J. Immunol.
93:6-12.
|
| 30.
|
Sellers, R. F.,
J. H. Bennett,
G. N. Mowat, and W. A. Snowdon.
1968.
Some factors affecting interferon production by foot-and-mouth disease virus in bovine tissue cultures.
Arch. Gesamte Virusforsch.
23:1-11[Medline].
|
| 31.
|
Strebel, K., and E. Beck.
1986.
A second protease of foot-and-mouth disease virus.
J. Virol.
58:893-899[Abstract/Free Full Text].
|
| 32.
|
Vilcek, J., and G. C. Sen.
1996.
Interferons and other cytokines, p. 375-399.
In
B. N. Fields, D. M. Knipe, and P. H. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa
|
Journal of Virology, December 1999, p. 9891-9898, Vol. 73, No. 12
0022-538X/99/$04.00+0
This article has been cited by other articles:
-
Randall, R. E., Goodbourn, S.
(2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol.
89: 1-47
[Abstract]
[Full Text]
-
de los Santos, T., Diaz-San Segundo, F., Grubman, M. J.
(2007). Degradation of Nuclear Factor Kappa B during Foot-and-Mouth Disease Virus Infection. J. Virol.
81: 12803-12815
[Abstract]
[Full Text]
-
Versteeg, G. A., van de Nes, P. S., Bredenbeek, P. J., Spaan, W. J. M.
(2007). The Coronavirus Spike Protein Induces Endoplasmic Reticulum Stress and Upregulation of Intracellular Chemokine mRNA Concentrations. J. Virol.
81: 10981-10990
[Abstract]
[Full Text]
-
Moraes, M. P., de los Santos, T., Koster, M., Turecek, T., Wang, H., Andreyev, V. G., Grubman, M. J.
(2007). Enhanced Antiviral Activity against Foot-and-Mouth Disease Virus by a Combination of Type I and II Porcine Interferons. J. Virol.
81: 7124-7135
[Abstract]
[Full Text]
-
de los Santos, T., de Avila Botton, S., Weiblen, R., Grubman, M. J.
(2006). The Leader Proteinase of Foot-and-Mouth Disease Virus Inhibits the Induction of Beta Interferon mRNA and Blocks the Host Innate Immune Response. J. Virol.
80: 1906-1914
[Abstract]
[Full Text]
-
Hohle, C., Karger, A., Konig, P., Giesow, K., Keil, G. M.
(2005). High-level expression of biologically active bovine alpha interferon by Bovine herpesvirus 1 interferes only marginally with recombinant virus replication in vitro. J. Gen. Virol.
86: 2685-2695
[Abstract]
[Full Text]
-
Bautista, E. M., Ferman, G. S., Gregg, D., Brum, M. C. S., Grubman, M. J., Golde, W. T.
(2005). Constitutive Expression of Alpha Interferon by Skin Dendritic Cells Confers Resistance to Infection by Foot-and-Mouth Disease Virus. J. Virol.
79: 4838-4847
[Abstract]
[Full Text]
-
Grubman, M. J., Baxt, B.
(2004). Foot-and-Mouth Disease. Clin. Microbiol. Rev.
17: 465-493
[Abstract]
[Full Text]
-
Afonso, C. L., Piccone, M. E., Zaffuto, K. M., Neilan, J., Kutish, G. F., Lu, Z., Balinsky, C. A., Gibb, T. R., Bean, T. J., Zsak, L., Rock, D. L.
(2004). African Swine Fever Virus Multigene Family 360 and 530 Genes Affect Host Interferon Response. J. Virol.
78: 1858-1864
[Abstract]
[Full Text]
-
van Pesch, V., Michiels, T.
(2003). Characterization of Interferon-{alpha} 13, a Novel Constitutive Murine Interferon-{alpha} Subtype. J. Biol. Chem.
278: 46321-46328
[Abstract]
[Full Text]
-
Sasaki, J., Nagashima, S., Taniguchi, K.
(2003). Aichi Virus Leader Protein Is Involved in Viral RNA Replication and Encapsidation. J. Virol.
77: 10799-10807
[Abstract]
[Full Text]
-
Ruggli, N., Tratschin, J.-D., Schweizer, M., McCullough, K. C., Hofmann, M. A., Summerfield, A.
(2003). Classical Swine Fever Virus Interferes with Cellular Antiviral Defense: Evidence for a Novel Function of Npro. J. Virol.
77: 7645-7654
[Abstract]
[Full Text]
-
Peng, C.-W., Napuli, A. J., Dolja, V. V.
(2003). Leader Proteinase of Beet Yellows Virus Functions in Long-Distance Transport. J. Virol.
77: 2843-2849
[Abstract]
[Full Text]
-
Chinsangaram, J., Moraes, M. P., Koster, M., Grubman, M. J.
(2002). Novel Viral Disease Control Strategy: Adenovirus Expressing Alpha Interferon Rapidly Protects Swine from Foot-and-Mouth Disease. J. Virol.
77: 1621-1625
[Abstract]
[Full Text]
-
Hinton, T. M., Ross-Smith, N., Warner, S., Belsham, G. J., Crabb, B. S.
(2002). Conservation of L and 3C proteinase activities across distantly related aphthoviruses. J. Gen. Virol.
83: 3111-3121
[Abstract]
[Full Text]
-
Zoll, J., Melchers, W. J. G., Galama, J. M. D., van Kuppeveld, F. J. M.
(2002). The Mengovirus Leader Protein Suppresses Alpha/Beta Interferon Production by Inhibition of the Iron/Ferritin-Mediated Activation of NF-{kappa}B. J. Virol.
76: 9664-9672
[Abstract]
[Full Text]
-
Peng, C.-W., Peremyslov, V. V., Mushegian, A. R., Dawson, W. O., Dolja, V. V.
(2001). Functional Specialization and Evolution of Leader Proteinases in the Family Closteroviridae. J. Virol.
75: 12153-12160
[Abstract]
[Full Text]
-
Sakoda, Y., Ross-Smith, N., Inoue, T., Belsham, G. J.
(2001). An Attenuating Mutation in the 2A Protease of Swine Vesicular Disease Virus, a Picornavirus, Regulates Cap- and Internal Ribosome Entry Site-Dependent Protein Synthesis. J. Virol.
75: 10643-10650
[Abstract]
[Full Text]
-
van Pesch, V., van Eyll, O., Michiels, T.
(2001). The Leader Protein of Theiler's Virus Inhibits Immediate-Early Alpha/Beta Interferon Production. J. Virol.
75: 7811-7817
[Abstract]
[Full Text]
-
Chinsangaram, J., Koster, M., Grubman, M. J.
(2001). Inhibition of L-Deleted Foot-and-Mouth Disease Virus Replication by Alpha/Beta Interferon Involves Double-Stranded RNA-Dependent Protein Kinase. J. Virol.
75: 5498-5503
[Abstract]
[Full Text]
-
Goodbourn, S., Didcock, L., Randall, R. E.
(2000). Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol.
81: 2341-2364
[Full Text]